AMPICILLIN FOR INJECTION, USP 2 G
AMPICILLIN (AMPICILLIN SODIUM) : 2 G · DIN 02226995 · FRESENIUS KABI CANADA LTD
Health Canada status: MARKETED
What is AMPICILLIN FOR INJECTION, USP?
AMPICILLIN FOR INJECTION, USP 2 G contains AMPICILLIN (AMPICILLIN SODIUM) : 2 G. It is listed in the Health Canada Drug Product Database under DIN 02226995, held by FRESENIUS KABI CANADA LTD, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 16-Aug-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AMPICILLIN FOR INJECTION, USP used for?
The treatment of infections due to susceptible gram-negative organisms (including strains of Shigellae, S. typhosa and other salmonellae, E. coli, H. influenzae, and P. mirabilis) and susceptible gram-positive organisms [including streptococci, pneumococci, and non-beta-lactamase (penicillinase) producing staphylococci]. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02226995 |
|---|---|
| Brand name | AMPICILLIN FOR INJECTION, USP |
| Generic / active ingredient | AMPICILLIN (AMPICILLIN SODIUM) : 2 G |
| Manufacturer | FRESENIUS KABI CANADA LTD |
| Strength | 2 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01CA01 AMPICILLIN |
| AHFS class | 08:12.16.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Aug-2019 |
| Original market date | 1998-07-27 00:00:00 |
How is it stored and handled?
Store the dry powder at controlled room temperature between 15 °C and 30 °C. Reconstituted solutions should be used within one hour when kept at controlled room temperature between 15 °C and 30 °C. Protect reconstituted solutions from freezing.
How is it supplied?
250 mg, 500 mg, 1 g and 2 g per vial
Is AMPICILLIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by TEVA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01CA01 AMPICILLIN. 17 of 56 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AMPICILLIN FOR INJECTION, USP | 1 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02227002 |
| AMPICILLIN FOR INJECTION, USP | 250 MG | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02227029 |
| AMPICILLIN FOR INJECTION, USP | 500 MG | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02227010 |
| AMPICILLIN SODIUM FOR INJECTION BP | 1 G | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02462338 |
| AMPICILLIN SODIUM FOR INJECTION BP | 1 G | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02530503 |
| AMPICILLIN SODIUM FOR INJECTION BP | 2 G | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02462346 |
| AMPICILLIN SODIUM FOR INJECTION BP | 2 G | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02530511 |
| AMPICILLIN SODIUM FOR INJECTION BP | 250 MG | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02462303 |
| AMPICILLIN SODIUM FOR INJECTION BP | 500 MG | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02530481 |
| AMPICILLIN SODIUM FOR INJECTION BP | 500 MG | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02462311 |
Who else supplies AMPICILLIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AMPICILLIN appears in 1362 registered pack listings across 7 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.